MED9 (mediator complex subunit 9) is a component of the Mediator complex, a coactivator essential for RNA polymerase II-dependent transcription of nearly all protein-coding genes. MED9 functions as part of a multiprotein scaffold that bridges gene-specific regulatory proteins to the basal transcription machinery, facilitating preinitiation complex assembly and transcription initiation 1. The protein exhibits activator-specific transcriptional requirements, with yeast Med9/Cse2 required specifically for Bas1/Bas2-mediated amino acid biosynthetic gene transcription 1. Alternative splicing generates MED9 isoforms with distinct expression patterns; endothelial progenitor cells express multiple MED9 transcripts 2, while familial dilated cardiomyopathy (DCM) patients show significantly reduced full-length MED9 with compensatory upregulation of a short MED9 isoform, suggesting isoform-specific roles in cardiac function 3. Clinically, de novo copy number variants affecting MED9 have been identified in congenital heart disease patients, implicating MED9 in cardiac development through interactions with established cardiac transcription factors like GATA4 4. Additionally, MED9 represents a potential viral target; computational analysis identified MED9 as a predicted target of SARS-CoV-2-derived microRNA-like sequences, suggesting possible regulatory roles during viral infection 5.